White C J, Kuter B J, Hildebrand C S, Isganitis K L, Matthews H, Miller W J, Provost P J, Ellis R W, Gerety R J, Calandra G B
Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Pediatrics. 1991 May;87(5):604-10.
A total of 3303 healthy children and adolescents, aged 12 months to 17 years, were vaccinated with one of five production lots of a live attenuated varicella vaccine (VARIVAX) containing 1000 to 1625 plaque-forming units per dose. The vaccine was generally well tolerated. Ninety-six percent (2381/2475) of vaccinees responded to vaccination by producing antibody as measured by a glycoprotein-based enzyme-linked immunosorbent assay; 99% (569/576) of those tested maintained antibody at 1 year following vaccination. The incidence of varicella following household exposure in vaccinees was approximately 12%; household contact historically results in 87% infection. Nearly all of the vaccinees who had varicella after vaccination had a clinically modified disease.
共有3303名12个月至17岁的健康儿童和青少年接种了五批生产批次之一的减毒活水痘疫苗（Varivax），每剂含1000至1625个空斑形成单位。该疫苗总体耐受性良好。通过基于糖蛋白的酶联免疫吸附测定法检测，96%（2381/2475）的接种者接种疫苗后产生抗体；99%（569/576）的检测对象在接种疫苗1年后仍保持抗体。接种疫苗者在家中接触水痘后水痘的发病率约为12%；以往家庭接触导致87%的感染率。几乎所有接种疫苗后患水痘的接种者都患有临床症状减轻的疾病。
